UCB’s Cimzia (certolizumab pegol) was recommended for approval by the European Committee for Medicinal Products (CHMP) for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Derm NPs and Pas
The fixed combination of halobetasol and tazarotene topicals significantly reduced the severity of localized disease with a favorable safety profile, shows a study published in the Journal of the American Academy of Dermatology.
As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.
Acute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.
Treating acne in pregnancy requires familiarity with FDA medication categories and having thorough discussions with patients.
A phase two study of adults with moderate-to-severe atopic dermatitis shows that once-daily oral Janus kinase (JAK) 1 and 2 inhibitor baricitinib relieved itch and improved sleep, a study shows.
Between 2004 and 2013, the number of spironolactone courses per 100 females with acne rose from 2.08 to 8.13 among dermatologists and from 1.43 to 4.09 among nondermatologists, researchers report.
Skin can act as a window to a patient’s general health says a physician writing in the journal Medicine. Changes may signal underlying disease from lupus to gastrointestinal disease.
Strong predictors for achieving a favorable actinic keratosis treatment response from ingenol mebutate 0.015% gel are dermoscopic detection of red pseudonetwork lesions and facial location, a study shows.
Female patients with hormonal acne that typically flares before or after menstrual cycles may be ideal candidates for spironolactone, said Emmy M. Graber, M.D., president of the Dermatology Institute of Boston who spoke at AAD 2018 in San Diego this week.